

Format for disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A Details of the Acquisition^

1.	Name of the Target Company (TC)	THYROCARE TECHNOLOGIES LIMITED		
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	HSBC Mutual Fund		
3.	Whether the acquirer belongs to Promoter/ Promoter group	No		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
5.	Details of the acquisition / disposal as follows	Number	% w.r.t. Total share/ voting capital wherever applicable (*)	% w.r.t. Total Diluted share/voting capital of the TC (**)
	Before the acquisition under consideration, holding of acquirer along with PACs of:			
	a) Shares carrying voting rights	75,57,935	4.75%	4.75%
	b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
	c) Voting rights (VR) otherwise than by shares	-	-	-
	d) Warrants/ convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	-	-
	Total (a+b+c+d)	75,57,935	4.75%	4.75%
	Details of acquisition			
	a) Shares carrying voting rights acquired	29,99,731	1.88%	1.88%
	b) VRs acquired otherwise than by equity shares	-	-	-
	c) Warrants/ convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
	d) Shares in the nature of encumbrance (Pledge/Lien/Non-Disposable undertaking/ Others)	-	-	-
	Total (a+b+c+/-d)	29,99,731	1.88%	1.88%
	After the acquisition, holding of acquirer along with PACs of:			
	a) Shares carrying voting rights	1,05,57,666	6.63%	6.63%
	b) VRs otherwise than by shares	-	-	-
	c) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-




	d) Shares in nature of encumbrance (Pledge/Lien/Non-Disposable undertaking/Others)	-	-	-
	Total (a+b+c+d)	1,05,57,666	6.63%	6.63%
6.	Mode of acquisition (e.g. open market/ public issue/ rights issue/ preferential allotment/ inter-se transfer/ encumbrances etc).	Shares Purchased		
7.	Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares etc.	N/A		
8.	Date of acquisition/ VR or date of receipt of intimation of allotment of shares/ warrants/ convertible securities/ any other instruments that entitles the acquirer to receive shares in the TC.	August 13, 2026		
9.	Equity share capital / total voting capital of the TC before the said acquisition	15,91,65,315		
10.	Equity share capital/ total voting capital of the TC after the said acquisition	15,91,65,315		
11.	Total diluted share/ voting capital of the TC after the said acquisition	29,99,731		

Part-B***

Name of the Target Company: Thyrocare Technologies Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
HSBC Mutual fund	No	

For HSBC Asset Management (India) Private Ltd.



Sumesh Kumar
Compliance Officer



Place: Mumbai
Date: August 17, 2026

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/ voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

August 17, 2026

National Stock Exchange of India Ltd.

Listing Department, Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Sub: Reporting under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011)

Dear Sir,

This is with reference to Regulation 29(1) and 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 wherein any acquirer who acquires shares or voting rights in a target company which taken together with shares or voting rights, if any, held by the company and by persons acting in concert in such target company, aggregating to 5% or more of the shares of such target company, is required to disclose their aggregate shareholding and voting rights in such target company.

In this regard, we wish to inform you that the shareholding of the scheme(s) of HSBC Mutual Fund ("the Fund") in Thyrocare Technologies Limited has exceeded 5%. We enclose herewith the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

We trust that you will find the above in order.

Thanking you,

Yours faithfully,

For HSBC Asset Management (India) Private Ltd.



Sumesh Kumar
Compliance Officer



Encl: As mentioned above

HSBC Asset Management (India) Private Limited

9-11th Floors, Nesco IT Park Building 3, Nesco Complex,
Western Express Highway, Goregaon (East) Mumbai 400063, India

Toll Free Number: 1800 200 2434 / 1800 4190 200

Email: investor.line@mutualfunds.hsbc.co.in

www.assetmanagement.hsbc.com/in

CIN - U74140MH2001PTC134220

Investment Manager to HSBC Mutual Fund